Publicaciones en colaboración con investigadores/as de Hospital Universitario San Jorge de Pereira (9)

2022

  1. Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study

    Medicine (United States), Vol. 101, Núm. 24, pp. E29252

2021

  1. Coexistence of immune-mediated diseases in sarcoidosis. Frequency and clinical significance in 1737 patients

    Joint Bone Spine, Vol. 88, Núm. 6

2020

  1. Evaluation of the Integrated Tuberculosis Research Program Sponsored by the Spanish Society of Pulmonology and Thoracic Surgery: 11 Years on

    Archivos de Bronconeumologia, Vol. 56, Núm. 8, pp. 483-492

2016

  1. Spanish Compliance With Guidelines for Prescribing Four Drugs in the Intensive Phase of Standard Tuberculosis Treatment

    Archivos de Bronconeumologia, Vol. 52, Núm. 5, pp. 262-268

2007

  1. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients

    Journal of Acquired Immune Deficiency Syndromes, Vol. 45, Núm. 4, pp. 439-444

  2. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients

    Journal of Viral Hepatitis, Vol. 14, Núm. 6, pp. 387-391

  3. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin

    Antiviral Therapy, Vol. 12, Núm. 4, pp. 469-476

  4. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 8, pp. 972-982

2005

  1. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C

    Antiviral Therapy, Vol. 10, Núm. 5, pp. 657-662